Our Meta 10 metabolic reprogramming platform for metabolic reprogramming of terminally exhausted T cells aims to develop recombinant protein drugs, antibody drugs, active peptides, nucleic acid drugs, and other treatments. The Meta 10 core technology of the platform aims to achieve cellular metabolic reprogramming by promoting oxidative phosphorylation of terminally exhausted T cells. This mechanism of action differs from PD-1 antibodies, which act only on precursor exhausted T cells. As a result, Meta 10 is the only known therapy under development that could target both precursor and terminally exhausted T cells, thereby achieving a full therapeutic response to cancer treatment.
Our lead candidate, IL-10-Fc recombinant protein, has shown great therapeutic potential and safety in multiple animal models for solid tumors. It also significantly improves efficacy when combined with T cell therapy, checkpoint inhibitors, immune agonists, and other immunotherapies. The preclinical efficacy of our biomacromolecular drugs has been published in several top international journals and has resulted in international patents. Currently, our therapeutic pipelines are being studied for druggability (trial production) or have entered the preclinical research stage.
